Sugi Predict

Sugi Predict / Compounds / SCHEMBL3344312

SCHEMBL3344312

SCHEMBL3344312

Cc1cc2c(cc1N)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ KDM4E B2RXH2 3/20 0.47
▸ MAPT P10636 8/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TSHR P16473 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ TDP1 Q9NUW8 3/20 0.41
▸ GAA P10253 3/20 0.41
▸ HSD17B10 Q99714 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ GRIA2 P42262 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362737 1.00 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL16253981 0.94 MAPT (0.51) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL30030734 0.86 MEN1 (0.47) ALDH1A1MAPTL3MBTL1TSHRCYP3A4
SCHEMBL1027495 0.86 MEN1 (0.47) ALDH1A1MAPTL3MBTL1TSHRCYP3A4
SCHEMBL8525889 0.82 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL572639 0.82 MAPT (0.56) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL23618815 0.79 DYRK1A (0.41) ALDH1A1MAPTSMN1; SMN2TSHRCYP3A4
SCHEMBL1702363 0.76 MAPT (0.42) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL3250820 0.76 MAPT (0.47) ALDH1A1KDM4EMAPTL3MBTL1LMNA
SCHEMBL29481812 0.76 MAPT (0.47) ALDH1A1KDM4EMAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 — — US claimed
US-8288552-B2 Dihydropyridone amidesas P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-10-16 — — US claimed
CN-116406272-A DNA-PK selective inhibitor and preparation method and application thereof 首药控股(北京)股份有限公司 2023-07-07 — — CN disclosed
CN-112313212-B OGA inhibitor compounds 詹森药业有限公司 2023-05-05 — — CN disclosed
EP-3810608-B1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-08-10 — — EP disclosed
CN-114195805-A DNA-PK selective inhibitor and preparation method and application thereof 首药控股(北京)股份有限公司 2022-03-18 — — CN disclosed
US-20210277003-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-09 — — US disclosed
US-20210130352-A1 OGA INHIBITOR COMPOUNDS JANSSEN-CILAG S.A. (ES) 2021-05-06 — — US disclosed
EP-3810586-A1 OGA INHIBITOR COMPOUNDS Janssen Pharmaceutica NV (BE) 2021-04-28 — — EP disclosed
CN-112313212-A OGA inhibitor compounds 詹森药业有限公司 2021-02-02 — — CN disclosed
WO-2019243533-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 — — WO disclosed
WO-2019243535-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 — — WO disclosed
US-10251827-B2 Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst L'OREAL (FR) 2019-04-09 — — US disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 — — US disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 — — US disclosed
WO-2014202787-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2014-12-24 — — WO disclosed
US-20130217664-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2013-08-22 — — US disclosed
WO-2013117645-A1 IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2013-08-15 — — WO disclosed
US-8372865-B2 Dihydropyridone amides as P2X7 modulators ROCHE PALO ALTO LLC (US) 2013-02-12 — — US disclosed
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251827-B2 Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst KRT18, CYB5R3, CBR3 ALDH1A1 444/4885KDM4E 1988/4885MAPT 1029/4885
US-20100160373-A1 DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS P2RY1, P2RX3, P2RX1 ALDH1A1 1115/4885KDM4E 2703/4885MAPT 2895/4885
US-20130217664-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES JAK1, IL6, JAK3 ALDH1A1 1175/4885KDM4E 3158/4885MAPT 4801/4885
US-20210277003-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN ALDH1A1 3839/4885KDM4E 1495/4885MAPT 7/4885
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST KRT18, CYB5R3, CBR3 ALDH1A1 441/4885KDM4E 1963/4885MAPT 863/4885
US-20210130352-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN ALDH1A1 3839/4885KDM4E 1495/4885MAPT 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.